Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gunjan L Shah

Showing results (41-50 of 130) with videos related to

Pageof 13
Sort By:
Transplantation and Cellular Therapy|October 8, 2023
Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell TherapyMaria-Stefania Infante, David Nemirovsky, Sean Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 31, 2017
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide MaintenanceMeighan Palazzo, Gunjan L Shah, Olivia Copelan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2020
Prognostic Factors for Postrelapse Survival after ex Vivo CD34<sup>+</sup>-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple MyelomaAlexandra Gomez-Arteaga, Gunjan L Shah, Raymond E Baser, et al.
Transplantation and Cellular Therapy|October 1, 2022
Pilot Trial of Homebound Hematopoietic Cell TransplantationHeather J Landau, Evelyn Orlando, Elizabeth S Rodriguez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2019
Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34<sup>+</sup> Selected Allogeneic Hematopoietic Cell TransplantationMichael Scordo, Valkal Bhatt, Patrick Hilden, et al.
Blood Advances|July 3, 2020
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortalityKitsada Wudhikarn, Martina Pennisi, Marta Garcia-Recio, et al.
Blood Neoplasia|July 12, 2026
CD8<sup>+</sup>CD38<sup>+</sup> T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlatesNezar Mehanna, Andriy Derkach, Billel Gasmi, et al.
Blood Advances|October 29, 2024
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomesYannis K Valtis, Sean Devlin, Roni Shouval, et al.
Blood Cancer Discovery|November 15, 2021
Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell TherapyRoni Tamari, Ioannis Politikos, David A Knorr, et al.
Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Pageof 13

Showing results (41-50 of 130) with videos related to

Sort By:
Pageof 13
Transplantation and Cellular Therapy|October 8, 2023
Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell TherapyMaria-Stefania Infante, David Nemirovsky, Sean Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 31, 2017
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide MaintenanceMeighan Palazzo, Gunjan L Shah, Olivia Copelan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2020
Prognostic Factors for Postrelapse Survival after ex Vivo CD34<sup>+</sup>-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple MyelomaAlexandra Gomez-Arteaga, Gunjan L Shah, Raymond E Baser, et al.
Transplantation and Cellular Therapy|October 1, 2022
Pilot Trial of Homebound Hematopoietic Cell TransplantationHeather J Landau, Evelyn Orlando, Elizabeth S Rodriguez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2019
Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34<sup>+</sup> Selected Allogeneic Hematopoietic Cell TransplantationMichael Scordo, Valkal Bhatt, Patrick Hilden, et al.
Blood Advances|July 3, 2020
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortalityKitsada Wudhikarn, Martina Pennisi, Marta Garcia-Recio, et al.
Blood Neoplasia|July 12, 2026
CD8<sup>+</sup>CD38<sup>+</sup> T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlatesNezar Mehanna, Andriy Derkach, Billel Gasmi, et al.
Blood Advances|October 29, 2024
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomesYannis K Valtis, Sean Devlin, Roni Shouval, et al.
Blood Cancer Discovery|November 15, 2021
Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell TherapyRoni Tamari, Ioannis Politikos, David A Knorr, et al.
Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Pageof 13